Arena Pharmaceuticals and Outpost Medicine have entered into a licensing agreement to advance an undisclosed, preclinical compound with potential utility in treating genitourinary disorders.  This compound, targeting an undisclosed G protein-coupled receptor (GPCR), was internally discovered by Arena.      “As we continue to focus on our potentially best-in-class pipeline, it is important that we seek opportunities to further develop and enhance the value of promising assets that d...